Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies : Episode 6
Future Predictions for Intravenous and Subcutaneous Biologics
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
EP: 1.Indication and Practical Utilization of IV and Subcutaneous Biologics
EP: 2.Key Consideration and Concerns Around IV and Subcutaneous Biologic Use
EP: 3.Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics
EP: 4.Key Patient Factors in Determining an Optimal Biologic Therapy
EP: 5.Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies
Now Viewing
EP: 6.Future Predictions for Intravenous and Subcutaneous Biologics
EP: 7.Overall Experience With Intravenous Biologics
EP: 8.Clinical Insights With Subcutaneous Biologics
EP: 9.Innovations Associated With IV Biologics
EP: 10.Exciting Developments With Subcutaneous Biologics
EP: 11.Positioning Intravenous and Subcutaneous Biologics
EP: 12.Adherence With Intravenous Biologics
EP: 13.Billing With Intravenous and Subcutaneous Therapies
EP: 14.Evaluating Efficacy Between Intravenous and Subcutaneous Biologics
EP: 15.Cost Considerations With Intravenous and Subcutaneous Biologics
EP: 16.Patient Experience With Intravenous and Subcutaneous Therapies
Video content above is prompted by the following questions:
- How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?
- Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?
Recent Videos
Related Content
